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The cytotoxic drugs cyclophosphamide (CPO) and ifosfamide (IFO) cause toxic 
urological effects due to the production of urinary metabolites that cause bladder 
inflammation. This study aimed to identify changes in the bladder afferent system 
following treatment with these drugs that might explain reported urological adverse 
effects. 
Intravesical pressure and afferent nerve activity were recorded during bladder distension 
and drug administration in isolated bladders from mice, 24 hours after intraperitoneal 
treatment with cyclophosphamide (100mg/Kg), ifosphamide (200mg/Kg) or saline 
(control). 
In isolated bladders, total afferent nerve activity at maximum bladder distension was 
increased from 182±13 imp/sec in control animals, to 230±14 imp/sec in CPO-treated 
(p<0.05) and 226±17 imp/sec in IFO-treated (P<0.001) mice.  Single fibre analysis 
revealed the increase resulted from an enhanced activity in low threshold, wide dynamic 
range fibres (23.3±1.9 imp/sec/fibre in controls to 31.5±2.5 (p<0.01) in CPO and 29.9±2.0 
imp/sec/fibre (p<0.05) in IFO treated).  CPO treatment was accompanied by an increase 
in urinary frequency in vivo, but was not associated with increases in urothelial release 
of ATP or acetylcholine, bladder compliance or spontaneous muscle activity. Also,CPO-
treatment did not affect afferent nerve responses or pressure responses to purinergic, 
muscarinic or nicotinic agonists. 
This is the first report of CPO and IFO-induced changes in specific populations of bladder 
afferents, namely an increase in low threshold, wide dynamic range fibres.  These effects 
appear to be direct and not secondary to increases in smooth muscle activity or the 
release of urothelial mediators. 
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Cyclophosphamide (CPO) and ifosfamide, IFO) are commonly used to treat a variety of 
malignant and non-malignant neoplastic diseases, as well as being used as 
immunosuppressive agents in bone marrow transplantation and chronic autoimmune 
disorders (Bergh 2003; Buda et al. 2003; de Jonge et al. 2005; Lawson et al. 2008; 
Nichols 1995; Sladek 1988).  Both CPO and IFO are inactive pro-drugs that must be 
activated, primarily in the liver to produce the cytotoxic agents, phosphoramide mustard 
and ifosforamide mustard respectively. During this process other small toxic metabolites 
such as acrolein are produced that are excreted in the urine and come into direct contact 
with the bladder urothelium, initiating an inflammatory response (Conklin et al. 2009).  
The functional effects of this inflammation can manifest as bladder pain, urinary 
frequency, urgency, dysuria and feelings of incomplete emptying as well as result in life 
threatening haemorrhagic cystitis (Fukuoka et al. 1991; Korkmaz et al. 2007). As such, 
these local urological effects are a major limiting factor in the clinical use of CPO and 
IFO. (Korkmaz et al., 2007; Coggins et al., 1960) 
Bladder sensation is mediated by sensory afferents embedded within the bladder wall, 
acting as tension receptors that respond to bladder stretch. As the adverse urological 
effects associated with CPO and IFO in humans are sensory in nature, and functional 
changes usually suggestive of hyperreflexia have been reported in animals treated with 
CPO or IFO (Andersson et al. 2008; Ito et al. 2008; Juszczak et al. 2009; Kageyama et 
al. 2008; Macedo et al. 2011; Okinami et al. 2014; Wang et al. 2008b), altered afferent 
signalling is considered a key component in the development of chemotherapy induced 
bladder dysfunction. However, few studies have examined the direct effects of CPO or 
IFO treatment on afferent nerve function and responsiveness. 
Dang et al., (2008) reported that CPO treatment causes increased activity of the pelvic 
nerve afferents during bladder distension (Yu and de Groat 2008), and whole-cell patch-
clamp recordings of isolated dorsal root ganglion neurones from CPO treated animals 
demonstrate lower thresholds for spike activation compared to controls (Yoshimura and 
de Groat 1999). Furthermore, several studies have shown bladder afferent fibres 
become sensitised by inflammation in-vivo (Habler et al. 1990; Rong et al. 2002; Xu and 
Gebhart 2008) or simulated inflammation in vitro (Xu & Gebhart; (2008).  
These studies provide evidence that afferent nerve activity is altered after CPO treatment 
and this is likely a consequence of inflammation. However, it remains to be established 
if bladder dysfunction following chemotherapy is related to total afferent output or the 
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sensitisation of a specific subpopulation of bladder afferent fibres; i.e. low-threshold 
fibres activated during physiological bladder filling versus high-threshold fibres involved 
in nociception. Furthermore, mediators such as ATP, acetylcholine (Ach) and 
prostaglandin E2 (PGE2) are released from the urothelium during bladder filling and 
influence sensory nerve activity and bladder function (Cockayne et al. 2000; Fry et al. 
2007).  However their role in chemotherapy induced bladder afferent sensitisation is 
unknown.  In addition, no studies to date have investigated the direct effect of IFO on 
bladder afferent firing.  
MATERIALS AND METHODS 
Animals: Young adult male C57/6B mice (3-5 months old) were treated intraperitoneally 
(100µL) with saline, CPO (100mg/kg) or IFO (200mg/kg). Animals were obtained from 
Griffith University with ethical approval from Griffith University Animals Ethics Committee 
(MSC/06/13) and the Bond University Ethics committee (Bond University ethics 
No.RO1762).  Animals were euthanised 24 hours after treatment by cervical dislocation 
in accordance with the guidelines of the National Health and Medical Research Council 
of Australia. 
Afferent Nerve Recording: The opened lower abdomen was secured in a 30mL bath 
continually superfused with Krebs solution (composition in mM: NaCl (188.4 mM), 
NaHCO3 (24.9 mM), glucose (11.7 mM), CaCl2 (1.9 mM), MgSO4 (1.2 mM) and KH2PO4 
(1.2 mM) gassed with 5% CO2 in oxygen, at a rate of 6mL/min and was maintained at a 
constant temperature of 35°C (Grundy et al. 2018; Chess-Williams et al., 2019).  The 
testes, prostate and surrounding connective tissues were dissected away from the 
bladder, the ureters were ligated and an intravesical canulae (OD 0.03IN) attached to a 
syringe pump (Genie, Kent, multi-phaserTM model NE-1000) allowing bladder distension 
by infusing isotonic saline (0.9%).  A two way catheter was inserted into the dome of the 
bladder to allow measurement of the intravesical pressure via a pressure transducer 
(DTXTM plus DT-XX, Becton Dickinson, Singapore) and to allow emptying of its contents 
via a two-way outflow tap.  
Pelvic and hypogastric nerves were dissected into fine multiunit branches as previously 
described (Grundy et al. 2018), and afferent activity was recorded via a suction electrode 
(tip diameter 25-50μm) attached to a Neurolog headstage (NL100, Digitimer Ltd, UK) 
connected to an AC pre-amplifier (NL014, Digitimer Ltd). Nerve activity was filtered 
(NL125, band pass filter, Digitimer Ltd) and passed through a 50/60Hz electrical noise 
eliminator (Humbug, Quest Scientific, Canada) to a Micro1401 analogue to digital 
This is a post-peer-review, pre-copyedit version of an article published in Archives of Toxicology. 




interface (Cambridge Electronic Design, UK) and then visualised on a computer using 
Spike2 software (version 7.1, Cambridge Electronic Design, UK). Whole nerve multi-fibre 
and individual unit afferent nerve activity was quantified using the Spike2 software. 
Experimental Protocol: The nerve preparation was left to stabilise for 30-60 minutes 
with the bladder empty.  With the outflow tap closed, the bladder was then distended by 
filling the bladder with saline (0.9% NaCl) at 30µl/min to a pressure of 40mmHg before 
opening the outflow tap allowing the bladder to empty. This was repeated every 10 
minutes until a stable pressure and afferent response to distension was observed.  The 
bladder was then distended at 30µl/min to 20mmHg and left with the outflow tap closed 
for 1 hour to allow accommodation of the volume and stabilisation of bladder tone and 
nerve activity.  After the detrusor tone and afferent activity stabilised, pharmacological 
agents were sequentially added to the bath allowing at least 30 minutes superfusion to 
wash the tissue between each drug addition to allow intravesical pressure and afferent 
responses to return to baseline. The following drugs were examined: ATP (1mM) 
(purinoceptor agonist), αβmethylene ATP (10μM) (P2X purinoceptor agonist), ACh (1μM) 
(muscarinic and nicotinic receptor agonist), carbachol (10µM) (muscarinic receptor 
agonist), DMPP (10μM) (nicotinic receptor agonist).  
In separate experiments the responses to ATP (1µM), αβmethylene ATP (10μM), 
carbachol (10µM) and DMPP (10µM) were repeated in the absence and presence of 
nifedipine (1µM) to block smooth muscle contraction.  These experiments were 
performed in control and CPO (100mg/kg) treated mice only.  The pressure and nerve 
responses remaining in the presence of nifedipine (1µM) were expressed as a 
percentage of the response in the absence of nifedipine. 
Mediator Release:  During collection of luminal and serosal samples for the assay of 
mediators, tissue superfusion was stopped and tissues were maintained in the 8mL bath 
of Krebs solution by gassing with 5% CO2 in oxygen.  Mediator release was measured 
in luminal contents following distention to 20mmHg with saline (stretch). A sample of the 
Krebs in the bath in contact with the bladder serosa was also collected and stored at -
20°C for later analysis.  Samples were collected onto dry-ice and assayed for ATP 
(Molecular Probes® A22066), Ach (Molecular Probes® A12217) and PGE2 (Cayman’s 
PGE2 EIA Kit) using commercially available kits. 
Afferent nerve activity: Multi-unit and single-unit nerve activity was quantified using 
Spike2 software. Baseline afferent activity was obtained by averaging the discharge in 
the 100 second period prior to the distension.  The afferent nerve response during 
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bladder distension was calculated by measuring the afferent activity (imp/sec) at each 
intravesical pressure increment up to 40mmHg.  
Spontaneous Contractions: During bladder filling phasic intravesical pressure 
increases were observed and these were associated with phasic changes in afferent 
nerve activity.  The frequency and amplitude of spontaneous contractions during filling 
were measured during the 200s preceding the intravesical pressure reaching 15mmHg. 
Voiding Analysis:  To determine if CPO treatment altered voiding behaviour, voiding 
analysis was performed on the mice before and after treatment, as previously described 
(West et al. 2018). All voiding pattern analysis was performed at the beginning the light 
cycle.  Mice were housed individually for 4 hours in cages lined with Filtech® Haless 
Filter Paper #225 with free access to food and water. Urine spots on the filter paper were 
detected using a Molecular Imager ChemiDoc XRS ultraviolet transilluminator 
(#720BR1293 BioRad, California USA). They were photographed, digitised, and 
analysed using Image J software.  
Statistical Analysis: Results are expressed as mean ± standard error of the mean 
(SEM).  Data were analysed using a Student t-test or one-way ANOVA with Dunnett or 
Tukey multiple comparisons test as appropriate, using Graphpad InStat (version 3.06) 
software (SanDiego, CA). Comparisons of whole response curves of control and treated 
groups were performed using two-way ANOVA with Bonferroni post-test. Significance 
levels were defined as p<0.05 (*), p<0.01 (**) and p<0.001 (***). 
RESULTS 
Before treatment, there was no significant difference in age or weight between animal 
groups, but both cytotoxic drug treatments resulted in weight loss after 24 hours (3.1 ± 
0.3%, p<0.01 for CPO and 3.4 ± 0.5%, p < 0.001 for IFO).  Average bladder volumes at 
maximum distension (40mmHg) were not different between the three groups. 
Cyclophosphamide and Ifosphamide sensitise mechanosensitive bladder 
afferents  
In order to determine if CPO induced bladder dysfunction is a consequence of altered 
bladder afferent mechanosensitivity, bladder afferent firing was recorded in response to 
bladder distension (Fig 1A&B).  As bladder volume increased, there was a corresponding 
increase in intravesical pressure and subsequent increase in bladder afferent nerve 
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activity.  Bladder filling typically included an initial compliant phase, (0 -15mmHg) which 
is characterised by a large increase in bladder volume for a relatively small increase in 
intravesical pressure that is accompanied by a significant increase in afferent nerve 
activity.  This phase was followed by a steep increase in pressure which was 
accompanied by a smaller increase in afferent nerve activity. The pattern of filling was 
highly reproducible and occurred in all bladders in all treatment groups.   
Treatment with CPO (100mg/kg, n=10) or IFO (200mg/kg, n=11) did not affect bladder 
compliance (Fig 1C), but did significantly enhanced total bladder afferent activity to 
distension compared to control mice (n=11, Fig 1D). There was no difference between 
the CPO and IFO treatment groups. The single units were identified in each preparation 
and the average number of distinct nerve fibres was not significantly different between 
treatment groups.  The single fibres were also classified based on their activation 
threshold and the number of both low and high threshold fibres was similar between 
groups.  Low threshold fibres were more numerous than high threshold fibres in all 
treatment groups (Fig 1E).  Accordingly, low threshold fibres made up 59.8±8.8% of the 
total fibre population in control bladders and while not significant, treatment with CPO or 
IFO showed a trend towards an increasing population of low threshold fibres to 76.5±7.1% 
and 75.8±6.3% respectively. 
Using single unit analysis to further characterise these differences revealed that the 
overall increases in afferent firing was due to an increase in the mechanosensitivity of 
individual units (Fig 1F).  Since the increase in afferent firing was not accompanied by 
any change in bladder compliance during distensions, bladder dysfunction following 
CPO is likely mediated by aberrant afferent firing, not through dysregulation of muscle 
function. Interestingly, the enhanced mechanosensitivity in CPO and IFO treated mice 
appears to be mediated by afferents activated at lower distension pressures (≤15mmHg) 
as the percentage difference in firing is maintained, but not further enhanced at higher 
distension pressures.  
Phasic contractions:  During bladder distension, phasic intravesical pressure changes 
were observed in some bladders (Fig 2), the numbers developing this activity being 
similar in all groups (8/11 control, 7/10 CPO and 7/11 IFO).  The frequency and amplitude 
of these phasic contractions were also similar in all experimental groups (Fig 2C and 2D).  
Interestingly, the phasic contractile activity was associated with very obvious phasic 
changes in afferent nerve activity (Fig 2B), but the relationship between phasic pressure 
change and nerve activity was unchanged by drug pretreatments, with the nerve activity 
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change per mmHg pressure change being similar in all groups (8.6±6.1, 13.4±6.7 and 
8.7±4.3 imp/sec/mmHg in control, CPO and IFO respectively). The spontaneous detrusor 
contractions persisted in the presence of tetrodotoxin (1μM) which abolished the nerve 
activity. 
Mediator Release:  Samples taken from the lumen of distended bladders and from the 
serosal solution surrounding the bladder were analysed for ATP and acetylcholine (Ach) 
content (Fig 3).  Each mediator concentration was then normalised to volume to obtain 
the total amount released.  More than 10 times the amount of ATP (pmoles) was released 
from the serosa than the lumen (p<0.001).  Similarly, the total amount of Ach was 
significantly higher (30-fold) in serosal samples than in luminal samples (p<0.01). 
Treatment with CPO (100mg/kg) did not affect the total amount of ATP or ACh released 
from either the lumen or the serosa of the mouse bladder (Fig 3).  However, treatment 
with IFO (200mg/kg) caused a reduction in the luminal ATP levels by 50% (p<0.05), but 
had no significant effect on ACh levels in either luminal or serosal samples.  
Single unit analysis ;To further characterise the single-unit subtypes responsible for 
CPO and IFO induced afferent hypersensitivity, individual fibres were classified based 
on their activation threshold (Fig 4).  Low threshold fibres had a greater firing rate at 
maximum distension compared to high threshold fibres (p<0.01).  A significant 
enhancement in the mechanosensitivity of low threshold single units following treatment 
was observed with CPO and  IFO (p<0.05). The activity of high threshold units, however, 
was unchanged after treatment with CPO or IFO. 
Amongst low threshold fibres, two distinct response patterns were observed (Fig 4). In 
the first pattern, low threshold afferents show a gradual increase in afferent excitability 
up to maximum distension, exhibiting a wide dynamic range (WDR). The second group 
demonstrated a narrower dynamic range where firing rate plateaued, or even decreased 
in activity after ≈15mmHg. These traditional low-threshold fibres were more numerous 
than WDR fibres in all animal groups.  Following treatment with CPO or IFO (all groups 
≥6 animals) , WDR fibres exhibited significantly enhanced mechanosensitivity (n=17, 20 
and 16 fibres for control, CPO and IFO), whilst treatments with either CPO or IFO had 
no effect on the activity of fibres with a narrow dynamic range (n=35, 28 and 28 fibres in 
control, CPO and IFO, Fig 4). These data indicate that the effects of CFO and IFO on 
mechanosensitivity and the subsequent changes in bladder voiding parameters are 
almost exclusively mediated by low threshold fibres with a wide dynamic range. 
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Response to Pharmacological Agents: Initially the bladder was filled to 20mmHg and 
left until pressure and nerve activity were stable in order to quantify the responses to 
various agonists.  Compliance of the bladder was unchanged by treatment with CPO 
(100mg/kg) or IFO (200mg/kg), but total nerve activity was increased at 20mmHg in both 
CPO and IFO treated animals, however the nerve activity adapted over time to be similar 
to the activity in control animals. Control, CPO and IFO-treated bladders stabilised to 
similar intravesical pressures (6.01±0.71mmHg, 6.96±0.65mmHg and 7.00±1.62mmHg 
respectively) and nerve firing rates (32.0±16.1imp/sec, 43.5±23.2imp/sec and 
24.2±7.62imp/sec respectively) after approximately 30 minutes.  The effects of 
pharmacological agents were then determined from this stable tension and afferent 
activity. 
In control preparations, extraluminal application of the purinergic agonists ATP (1mM) 
and αβmATP (10µM) and the cholinergic agonists ACh (1µM) and carbachol (10µM) 
elicited significant rises in intravesical pressure and afferent nerve activity (Fig 5).  DMPP 
(10µM), a nicotinic agonist, produced a large increase in nerve activity but only a small 
increase in intravesical pressure that was small compared to the other agonists.  
Treatment with CPO or IFO treatment did not significantly affect either pressure 
responses or afferent nerve responses to any of the agonists (Fig 5). 
Responses to the agonists were also examined in the presence of nifedipine (1uM) in 
bladders from control and CPO treated animals. In control bladders, nifedipine (1µM) 
significantly reduced the intravesical pressure responses to ATP (1mM), αβmATP (10µM) 
and carbachol (10µM) (Fig 6).  Nifedipine reduced responses to DMPP from 
0.37±0.27mmHg to 0.07±0.05mmHg, but due to the small magnitude of the responses 
these changes were not statistically significant.  In contrast to the significant reduction in 
muscle contraction to these agents, nifedipine had less effect on nerve responses and 
only reduced the responses to carbachol (10nM) (p<0.05).   
Nifedipine reduced intravesical pressure responses to a similar extent in both control and 
CPO treated bladders.  The reductions of pressure responses to the agonists by 
nifedipine were similar in bladders from control and CPO treated animals (ATP, 83±8% 
vs 72±8%; αβmATP 75±5% vs 78±8%; carbachol 80±1% vs 82±2%; DMPP 94±5% vs 
98±1% respectively).  In these bladders from CPO treated animals, nerve activity again 
was less affected than pressure responses by nifedipine (1µM), and reductions in 
responses were again similar for bladders from control and treated animals for ATP 
(37±14% vs 16±28%); αβmATP (18±13% vs 38±5%); carbachol (49±10% vs 54±10%). 
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Voiding function:  To measure bladder function in vivo, the voiding patterns of control 
and CPO treated mice were investigated. During the 4 hour voiding analysis period, urine 
production was similar in the control and CPO treated animals, but the total number of 
voids was significantly greater (P<0.05) in the CPO-treated animals (66.9±17.8) than in 




CPO is used in patients to treat a number of conditions, but urinary adverse effects are 
common due to metabolites such as acrolein and chloroacetaldehyde (CAA), which 
irritate the bladder (Mills et al., 2019).  For this reason, the drug is also commonly used 
in animals as a model of bladder inflammation.  Acrolein and CAA are thought to 
influence bladder function after delivery in the urine, however urothelial mediator release 
was unchanged suggesting urothelial function, and possibly barrier function, are normal.  
An alternative possibility is that the metabolites exert their actions on bladder structures 
following delivery in the blood via capillaries in the suburothelium putting the toxins in 
close proximity with the sensory nerves. 
Several studies have used CPO or IFO to treat cancer in murine models and the reported 
doses range between 30mg/kg – 200 mg/kg intraperitoneally for CPO (Harnack et al. 
2011; Kusnierczyk et al. 1999; Ma et al. 2011) and 60 - 350 mg/kg intraperitoneally for 
IFO (Brucker and Sieg 1999; Silbermann et al. 1990; Wang et al. 2008a; Yamada et al. 
2009).  For this study, a CPO dose of 100mg/kg and an IFO dose of 200mg/kg were 
chosen which fall within the doses used for cancer treatments in mice.   
Treatment of mice with CPO or IFO did not affect bladder compliance, but did enhance 
total afferent nerve firing during bladder distension.  Although activity was enhanced at 
maximum distension, a greater enhancement was observed at lower intravesical 
pressures of around 15mmHg.  An intravesical pressure of 15mmHg corresponds to the 
approximate micturition threshold in mice (Igawa et al. 2004).  Therefore, it appears the 
effects of CPO and IFO on afferent activity are most apparent during typical physiological 
filling. An increase in afferent activity by CPO in the rat has been reported previously (Yu 
and de Groat 2008), but in that study a marked variability was found between the afferent 
responses that was thought to be due to variation in the number of fibres present in the 
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afferent branch during recording. An increase in firing of DRG neurones from CPO 
treated rats also suggested this mechanism (Dang et al. 2008; Yoshimura and de Groat 
1999).  Accordingly, the present study investigated directly whether increased afferent 
activity after CPO or IFO treatment is due to increased firing of individual fibres or rather 
an overall increase in fibre density. The number of fibres in our study was similar in all 
groups and the enhanced nerve activity after CPO and after IFO was shown to occur in 
individual fibres. 
A number of classification systems exist for afferent fibres.  One is based on whether the 
fibres become active at low (<15mmHg) or high (>15mmHg) intravesical pressures (Daly 
et al. 2007; Rong et al. 2002; Shea et al. 2000).  Stretch sensitive bladder afferent nerves 
have also been classified based on their functional response patterns where fibres 
respond over a wide dynamic range (WDR) increasing to maximum stretch, or they may 
only respond over a more limited narrower dynamic range and reach peak activity at 
lower than maximum stretch.  These types have also been referred to as encoding and 
non-encoding fibres respectively (Shea et al., 2000). Both response patterns have been 
shown previously in mice (Xu and Gebhart 2008) with the narrower range fibres being 
more common.  The present study found that 60-75% of all fibres were low threshold, a 
figure similar to previous reports (Daly et al., 2007, Rong et al., 2002).  
All high threshold fibres demonstrated a firing pattern with activity that increased 
continuously up to maximum distension as reported by Xu & Gebhart (2008), while both 
firing patterns were observed in the low-threshold nerves with the narrower dynamic 
range fibres being more common.  Treatment with CPO or IFO enhanced the activity of 
the low threshold fibres, but not the high threshold fibres  Exposure to an inflammatory 
medium in vitro has been shown to reduce the response threshold of high threshold 
fibres to a level comparable to that of the low threshold fibres (Xu & Gebhart (2008).  
Interestingly, the response pattern of some of the narrow range low threshold fibres also 
changed after exposure to the inflammatory environment with fibres responding up to 
maximum stretch.  In the present study separate mice were treated with saline, CPO or 
IFO and accordingly it was not possible to determine whether the drugs lowered the 
activation threshold of high threshold fibres.  However, the percentage of low threshold 
fibres appeared to be increasing after treatment, which may suggest that some narrow 
dynamic range fibres may have been altered by CPO or IFO. 
Typically, low threshold fibres are thought to contribute to normal micturition reflexes and 
high threshold fibres to painful sensations.  However, given that low threshold fibres can 
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encode stretch stimuli into the pain/noxious range (>15mmHg) and can sensitise, it 
appears possible they may also contribute to painful sensations.  Accordingly, the 
increased activity of low threshold fibres after CPO or IFO treatment may explain the 
bladder hyperactivity (urgency, frequency), abnormal sensations (residual volume) as 
well as the painful sensations experienced by patients following treatment with these 
cytotoxic drugs.  Furthermore, high threshold fibres becoming active at lower thresholds 
could also explain abnormal sensations of fullness and pain at lower bladder volumes.  
The mechanism of the CPO/IFO induced bladder afferent nerve hypersensitivity is 
unknown.  Various mediators released by the urothelium can activate and sensitise 
afferent nerves and may possibly sensitise afferent nerves after CPO/IFO treatment.  It 
was observed that mediator levels were higher at the serosal surface than the luminal 
surface, confirming a previous study using Ussing chambers (Fergusson et al., 1997).  
The detrusor muscle can release a small amount of ATP when stretched but the greatest 
release comes from the cells of the mucosa (Cheng et al., 2011). It is likely that the lower 
levels at the luminal surface may reflect the barrier function of the urothelium which could 
limit diffusion into the lumen.  A previous study found enhanced ATP release following 
multiple, high doses of CPO (Smith et al., 2005), but with the single lower dose of CPO 
used in the present study, changes in urothelial mediator release were not observed.  It 
was not possible to measure mediator release at the suburothelium, and thus indirect 
actions via mediators cannot be completely excluded, but it would seem unlikely since 
mediator levels were unchanged at the luminal and serosal bladder surfaces following 
CPO and IFO treatment. 
Interestingly in DRG from CPO treated rats, P2X3 receptors have been found to be up-
regulated and a greater number of neurones responded to purinergic agonists (Dang et 
al. 2008), suggesting normal levels of ATP release could still possibly produce enhanced 
nerve activity.  However our study showed that nerve and pressure responses to 
purinergic agonists, both ATP and αβmATP were similar in all experimental groups. Also, 
when nifedipine was used to depress smooth muscle contractions and isolate the nerve 
responses, these purinergic afferent responses were not altered following CPO or IFO 
treatment.  This again indicates that changes in mediator release or action do not explain 
the afferent hypersensitivity observed in the current study. 
Although nerve activity was increased at 20mmHg after CPO or IFO treatment, the firing 
rate in both treatment groups was able to accommodate over time to a level comparable 
to controls.  This gave a fairly consistent baseline firing rate from which responses to 
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various agonists could be assessed.  Both the purinergic agonists (ATP, αβmATP) 
increased intravesical pressure and afferent nerve activity, which is not surprising given 
that bladder smooth muscle and afferent nerves express purinergic receptors and 
activation causes neurone depolarisation triggering action potentials (Dang et al. 2008).  
The effect of nifedipine on purinergic responses was the same in bladders from control 
and CPO-treated animals, reducing both the pressure and nerve responses in a similar 
fashion.  Accordingly, the contribution of muscle tone to purinergic afferent nerve 
responses is the same after CPO treatment.  
Muscarinic nerve responses to carbachol (and Ach) were also associated with an 
increase in intravesical pressure, both responses increasing and recovering to baseline 
at a similar rate.  Nifedipine depressed pressure responses to carbachol, but this was 
accompanied by reduced nerve responses, indicating that unlike purinergic responses, 
at least a part of the muscarinic response is mediated indirectly via changes in smooth 
muscle tone.  The total nerve activity is a combination of mechanical stimulation due to 
muscle contraction plus direct nerve stimulation by the agonists.  This can be seen with 
nerve responses to carbachol which were greatly reduced as nifedipine reduced the 
contractile response.  However, for the purinergic agonists and nicotine the greatest 
effects are on the nerve itself and thus nifedipine has less of an influence on nerve 
responses to these agonist. Yu and Groat (2010) also reported that intravesical 
muscarinic agonists increase afferent nerve activity during bladder distention but not in 
the absence of bladder distention (Yu and de Groat 2010), whilst Daly et al. (2010) found 
that muscarinic receptor stimulation during bladder distension significantly inhibited 
afferent firing.  Accordingly, the effects of muscarinic receptor stimulation on afferent 
firing are still unclear.  To add to the confusion, muscarinic receptors are present on 
urothelial cells and can cause the release of excitatory mediators such as ATP (Nile and 
Gillespie 2012; Yokoyama et al. 2011) and thus elicit indirect activation of the afferent 
nerves.  In terms of muscle tone contributing to afferent nerve response, both control 
and CPO groups demonstrated similar reductions in pressure and nerve responses after 
nifedipine, again suggesting that in CPO-treated bladders the relationship between 
muscle tone and nerve responses is unchanged.  
In contrast, the direct effects of nicotinic receptor stimulation with DMPP were very clear.  
DMPP had almost no effect on pressure, but elicited large increases in nerve activity in 
the absence and in the presence of nifedipine.  Nicotinic receptors particularly the α3-
containing subtype are expressed in bladder sensory nerves in mice (Nandigama et al. 
2013) and nicotinic afferent nerve responses have been reported previously (Masuda et 
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al. 2006; Beckel & Birder, 2012).  However their function in CPO-induced inflammatory 
responses has never been investigated.  In the present study, CPO or IFO treatment did 
not significantly affect any of the responses to the various agonists, indicating that the 
enhanced nerve activity during distention in treated animals was not due to an increase 
in nerve sensitivity to purinergic or cholinergic stimulation. 
Spontaneous phasic pressure changes were observed in some bladders in all 
experimental groups and were associated with phasic nerve activity which mimicked the 
muscle activity.  The neurotoxin tetrodotoxin abolished nerve responses without affecting 
phasic muscle contractions, further demonstrating the influence of muscle tension on 
afferent nerve activity (McCarthy et al. 2009; Zagorodnyuk et al. 2007).  The results of 
the present study demonstrated that treatment with CPO or IFO did not significantly 
affect the frequency or amplitude of spontaneous contractions during filling or 
accommodation of the bladder. It has been suggested that spontaneous contractions 
play a significant role in generating afferent activity (Heppner et al., 2016) and the 
possibility that the relationship between phasic contractions and nerve activity may have 
been altered following treatment was investigated. The increase in nerve activity when 
expressed as the increase in impulses for each mmHg rise in pressure during phasic 
contractions was unchanged following CPO or IFO treatment, indicating that the 
relationship was not affected by these drug treatments.  Thus neither spontaneous 
contractions nor the nerve activity associated with this phasic activity were altered by 
drug pretreatments. 
When the voiding patterns of animals was examined over a 4 hour period, there was an 
increase in voiding frequency following CPO treatment without any change in the volume 
of urine produced.  Thus the increased bladder afferent activity in these animals was 
associated with increased micturition supporting the hypothesise that the symptoms of 
urgency and frequency observed in patients following CPO treatment result from an 
afferent nerve sensitisation with exaggerated afferent input to the spinal cord triggering 
the micturition reflex at lower distension pressures. 
In conclusion, CPO and IFO treatment enhanced total nerve activity in the mouse bladder 
during graded distensions and this was due to enhanced activity of the low threshold 
wide dynamic range fibres.  In addition, an increased ability of low threshold fibres to 
respond into the noxious range of bladder pressures may also be involved in the 
enhanced activity.  This is the first study to report the effects of CPO and IFO on low and 
high threshold pelvic sensory nerves in the mouse bladder.  The increased afferent 
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activity does not appear to be due to enhanced responses to urothelial ATP or 
acetylcholine but rather appears to be due to a direct sensitisation of the nerves to 
distension. 
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Fig 1 Experimental trace showing [A] bladder intraluminal pressure in mmHg, and [B] 
nerve activity in impulses/sec during two repeated bladder distensions to 40mmHg.  [C] 
Compliance and [D] afferent nerve activity during filling of isolated bladders from mice 
pretreated with saline (control), CPO (100mg/ml) or IFO (200mg/ml). Data represented 
as mean ± SEM (n≥6). Analysed by two-way ANOVA (*p<0.05 vs comparable control 
activity at individual pressure interval, ###p<0.001 vs whole control curve).  [E] Mean (± 
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SEM) percentage of nerves classified as low threshold in saline, CPO or IFO treated 
mice (n≥6). [F] Mean (± SEM) maximum nerve activity (imp/sec) per individual nerve 
fibre during bladder distension at 40mmHg in bladders from saline, CPO or IFO-treated 
mice. (n≥6).  Analysed by one-way ANOVA with Dunnett post test (*p<0.05, **p<0.01 vs 
control). 
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Fig 2: Figure 2: Enlarged trace showing the development of phasic contractile activity (B) 
during bladder filling and its association with changes in afferent nerve activity (A).  This phasic 
contractile activity occurred in about 75% of bladders in all experimental groups.   Also shown 
are the mean (±SEM) frequency and amplitude values for phasic contractile activity in the 
three experimental groups (n=10-11). 
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Fig 3: Mean (±SEM) intraluminal (open columns) and serosal (bath) (solid columns) ATP 
and Ach release at maximal distension of bladders from mice treated with saline or CPO 
(100mg/kg). * P<0.05 compared with corresponding control value, analysed using paired 
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Fig 4 Afferent nerve activity of [A] low threshold (n≥44) and [B] high threshold fibres 
(n>10) in bladders from control and CPO (100mg/ml) or IFO (200mg/ml) treated animals. 
Data represented as mean ± SEM and analysed by two-way ANOVA (***p<0.001 vs 
control).  Afferent nerve activity in low threshold [C] wide dynamic range (WDR) fibres 
and [D] narrow dynamic range (NDR) fibres (n≥17) in control, CPO and IFO-treated 
animals. Data represented as mean ± SEM and analysed by two-way ANOVA 
(***p<0.001 vs control curve). 
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Fig 5 Experimental trace showing control pressure [A] and nerve responses [B] to 
various agonists. [C] Mean pressure responses and [D] mean nerve responses for 
bladders from control, CPO and IFO-treated animals to ATP (1mM), αβmATP (10µM), 
ACh (1µM), carbachol (10µM) and DMPP (10µM). Data represented as mean ± SEM 
(n=≥5).  Responses were similar in bladders from control, CPO and IFO treated animals.  
Analysed by one way ANOVA with Dunnett post test (*p<0.05 vs control response for 
each drug). 
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Fig 6 The effect of nifedipine (1µM) on control [A] bladder pressure and [B] total afferent 
nerve responses to ATP (1mM), αβmATP (10µM), carbachol (10µM) and DMPP (10µM).  
Data represented as mean ± SEM (n≥4) and analysed by paired two-tailed t-test (*p<0.05, 
**p<0.01 vs absence of nifedipine)   
 
